Sonoma Pharma (SNOA): Growth-Adjusted Market Cap to Net Income

Corporate company logo of Sonoma Pharmaceuticals (SNOA)

Sonoma Pharmaceuticals relies on production outsourcing via CMOs, which confirms the flexibility of its model. The average peg_co level visualizes this trend, where the value 0.00 captures the metric level. However, rising raw material costs and expensive marketing are squeezing margins, while management is successfully expanding the distribution of over-the-counter drugs to optimize expenses.

PEG Multiple: Sonoma Pharma (SNOA) for 07/04/2022 - 11/17/2026

Metric breakdowns and analytics for Sonoma Pharma (SNOA)

Fundamental company analysis:SNOA - Sonoma Pharmaceuticals
Manufactured products of Sonoma Pharmaceuticals Inc.

The PEG ratio measures business value relative to net income growth rates, where a value below one signals a fundamental undervaluation of the asset. The current P/E to projected growth ratio for Sonoma Pharmaceuticals (SNOA) stands at 0.00, confirming the effectiveness of Sonoma Pharmaceuticals (SNOA) investments in a highly qualified staff of chemists and dermatologists to scale sales and capitalize on intellectual resources.